ArticleBMC cancer2025
VETC predicting model based on CE-CT can predict prognosis and assisting treatment plan for solitary HCC: better together with radiomics.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomics-Based AI for the Diagnosis and Prognosis of Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesNoninvasive evaluation and treatment of vessels encapsulating tumor cluster (VETC) HCCs remain challenging. Herein, a new Clinic-Radiologic-Intratumor Radiomics (CRIR) model was investigated for the preoperative prediction of VETC-HCCs and prognosis based on CE-CT, then compared therapeutic outcomes between predicted VETC and nonVETC-HCCs after different treatment methods.
methodsTotal 456 HCC patients who underwent radical resection (RR), liver transplantation (LT) or TACE were retrospectively included in this multicenter (Center 1–4) study between January 2014 and November 2022. The intratumor and 1 cm peritumor VOI were segmented in the three phases of CE-CT imaging. Radiomics features were selected using LASSO and multivariable logistic regression (LR) to filtered the useful features. Clinical, radiological qualitative and quantitative features, intratumor, peritumor and combined radiomics, were established using LR into Clinic-radiological (CR), intratumor radiomics (IR), peritumor radiomics (PR), CRIR, Clinic-radiological- peritumor radiomics (CRPR)and CR-intra and peritumor radiomics (CRIPR) models. Diagnostic performance was calculated and compared for the models. Kaplan–Meier survival analysis was used to assess progression state in model-predicted VETC-HCCs and non-VETC-HCCs in TACE, or early recurrence in both pathologic and model-predicted in RR or LT groups. Additionally, outcomes between the RR and LT groups were compared to determine the optimal treatment approach.
resultsNeutrophil-to-lymphocyte ratio (NLR) (P = 0.031), gamma-glutamyl transferase (GGT) (P = 0.043), intratumor necrosis (P = 0.026), Arterial enhancement fraction (AEF) (P = 0.038), and intra-tumoral artery (P = 0.035) were independent predictors of VETC-HCC. CRIR model showed best area under the ROC curve value (0.85-080 across training, internal test, and external test), statistically significant improvement over the clinico-radiologic model, but not the CRIPR model. In patients with pathologic VETC-HCC, those treated with RR exhibited higher early recurrence rate compared to those treated with LT (P = 0.029). On the contrast, the early recurrence rates in patients with pathologic non-VETC-HCC, were similar between the RR and LT groups (P > 0.05). Similarly, the early recurrence rates in patients with CRIR model predicted VETC-HCC or non-VETC-HCC presented same trend as pathologic group. In application (TACE) group, CRIR model predicted VETC-HCC had lower tumor response rate (50.00% vs. 75.56%, P < 0.001) and worse PFS (17 months vs. 30 months; P = 0 0.039) than those with non-VETC HCCs.
conclusionThe CRIR model provides accurate preoperative identification of VETC-HCC and offers prognostic value for early recurrence following RR or LT, tumor response after TACE and surgical approach selection between RR and LT in solitary HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.